Clinical Trial Update: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation in hormone receptor-positive, HER2-positive op…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Docetaxel (Taxotere) (docetaxel)
• Pertuzumab (Perjeta) (pertuzumab)
• Trastuzumab (Herceptin) (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2023-06-12